Signal Detection of Potential Hepatotoxic Drugs: Case-Control Study Using Both a Spontaneous Reporting System and Electronic Medical Records

被引:10
作者
Akimoto, Hayato [1 ]
Nagashima, Takuya [1 ]
Minagawa, Kimino [2 ]
Hayakawa, Takashi [1 ]
Takahashi, Yasuo [2 ]
Asai, Satoshi [1 ]
机构
[1] Nihon Univ, Sch Med, Dept Biomed Sci, Div Pharmacol,Itabashi Ku, 30-1 Oyaguchi Kamicho, Tokyo 1738610, Japan
[2] Nihon Univ, Clin Trials Res Ctr, Sch Med, Div Genom Epidemiol & Clin Trials,Itabashi Ku, 30-1 Oyaguchi Kamicho, Tokyo 1738610, Japan
关键词
drug-induced liver injury; hepatotoxicity; signal detection; case-control study; electronic medical record; Japanese Adverse Event Report Database (JADER); INDUCED LIVER-INJURY; POPULATION; THERAPY; IMPACT; EVENT; DATABASES; CHILDREN; OUTCOMES; EXAMPLE; RATIOS;
D O I
10.1248/bpb.b21-00407
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Drug-induced liver injury (DILI) is a common adverse drug event. Spontaneous reporting systems such as the Japanese Adverse Event Report Database (JADER) have been used to evaluate the association between drugs and adverse drug events. However, the association of drugs with adverse drug events may be overestimated due to reporting biases. Therefore, it is important to objectively evaluate the association using liver function test values. The aim of the present study was to predict potential hepatotoxic drugs using real-world data including electronic medical records and the JADER database. A total of 70009 (2779 with DILI and 67230 without DILI) and 438515 (10235 with DILI and 428280 without DILI) Japanese adult patients were extracted from electronic medical records and the JADER database, respectively. Drugs with >= 100 DILI patients in both of the two databases were regarded as suspected drugs for DILL We used multivariate logistic regression to evaluate the association between the suspected drugs and increased risk of DILI. Among the suspected drugs, broad-spectrum antibiotics such as meropenem, tazobactam/piperacillin and ceftriaxone were signilicantly associated with an increased risk of DILI, and meropenem had a greater risk of DELI in both of the two databases. Additionally, there were significant associations of mosapride and L-carbocisteine with increased risk of DILL In addition to well-known associations between antibiotic drugs and DILL mosapride and L-carbocisteine were found to be new potential signals of drugs causing hepatotoxicity. This study indicates potential hepatotoxic drugs that require further causality assessment.
引用
收藏
页码:1514 / 1523
页数:10
相关论文
共 56 条
  • [1] Analysis of 307 cases with drug-induced liver injury between 2010 and 2018 in Japan
    Aiso, Mitsuhiko
    Takikawa, Hajime
    Tsuji, Keiji
    Kagawa, Tatehiro
    Watanabe, Masaaki
    Tanaka, Atsushi
    Sato, Ken
    Sakisaka, Shotaro
    Hiasa, Yoichi
    Takei, Yoshiyuki
    Ohira, Hiromasa
    Ayada, Minoru
    Hashimoto, Etsuko
    Kaneko, Shuichi
    Ueno, Yoshiyuki
    Ohmoto, Kenji
    Takaki, Akinobu
    Torimura, Takuji
    Matsuzaki, Yasushi
    Tajiri, Kazuto
    Yoneda, Masashi
    Ito, Takayoshi
    Kato, Naoya
    Ikejima, Kenichi
    Mochida, Satoshi
    Yasuda, Hiroshi
    Sakamoto, Naoya
    [J]. HEPATOLOGY RESEARCH, 2019, 49 (01) : 105 - 110
  • [2] Identification and Characterization of Cefazolin-Induced Liver Injury
    Alqahtani, Saleh A.
    Kleiner, David E.
    Ghabril, Marwan
    Gu, Jiezhun
    Hoofnagle, Jay H.
    Rockey, Don C.
    [J]. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2015, 13 (07) : 1328 - +
  • [3] EASL Clinical Practice Guidelines: Drug-induced liver injury
    Andrade, Raul J.
    Aithal, Guruprasad P.
    Bjornsson, Einar S.
    Kaplowitz, Neil
    Kullak-Ublick, Gerd A.
    Karlsen, Tom H.
    [J]. JOURNAL OF HEPATOLOGY, 2019, 70 (06) : 1222 - 1261
  • [4] Drug-induced liver injury:: An analysis of 461 incidences submitted to the Spanish Registry over a 10-year period
    Andrade, RJ
    Lucena, MI
    Fernández, MC
    Pelaez, G
    Pachkoria, K
    García-Ruiz, E
    García-Munoz, B
    González-Grande, R
    Pizarro, A
    Durán, JA
    Jiménez, M
    Rodrigo, L
    Romero-Gomez, M
    Navarro, JM
    Planas, R
    Costa, J
    Borras, A
    Soler, A
    Salmerón, J
    Martin-Vivaldi, R
    [J]. GASTROENTEROLOGY, 2005, 129 (02) : 512 - 521
  • [5] Arakawa K, 2019, J TOXICOL SCI, V44, P833, DOI 10.2131/jts.44.833
  • [6] Pharmacovigilance in oncology
    Baldo, Paolo
    Fornasier, Giulia
    Ciolfi, Laura
    Sartor, Ivana
    Francescon, Sara
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2018, 40 (04) : 832 - 841
  • [7] Outcome and prognostic markers in severe drug-induced liver disease
    Björnsson, E
    Olsson, R
    [J]. HEPATOLOGY, 2005, 42 (02) : 481 - 489
  • [8] Categorization of Drugs Implicated in Causing Liver Injury: Critical Assessment Based on Published Case Reports
    Bjornsson, Einar S.
    Hoofnagle, Jay H.
    [J]. HEPATOLOGY, 2016, 63 (02) : 590 - 603
  • [9] Incidence, Presentation, and Outcomes in Patients With Drug-Induced Liver Injury in the General Population of Iceland
    Bjornsson, Einar S.
    Bergmann, Ottar M.
    Bjornsson, Helgi K.
    Kvaran, Runar B.
    Olafsson, Sigurdur
    [J]. GASTROENTEROLOGY, 2013, 144 (07) : 1419 - U168
  • [10] Profiling Cumulative Proportional Reporting Ratios of Drug-Induced Liver Injury in the FDA Adverse Event Reporting System (FAERS) Database
    Brinker, Allen D.
    Lyndly, Jenna
    Tonning, Joseph
    Moeny, David
    Levine, Jonathan G.
    Avigan, Mark I.
    [J]. DRUG SAFETY, 2013, 36 (12) : 1169 - 1178